S&P 500   4,269.23 (-0.34%)
DOW   33,663.14 (+0.27%)
QQQ   350.24 (-1.30%)
AAPL   177.97 (-0.69%)
MSFT   324.12 (-2.87%)
META   266.24 (-1.80%)
GOOGL   122.85 (-3.50%)
AMZN   122.36 (-3.36%)
TSLA   226.30 (+2.25%)
NVDA   382.27 (-1.10%)
NIO   7.78 (-1.27%)
BABA   85.40 (-1.50%)
AMD   119.44 (-3.86%)
T   15.91 (+1.53%)
F   13.49 (+4.33%)
MU   67.33 (-0.31%)
CGC   0.73 (-1.69%)
GE   106.53 (+1.01%)
DIS   92.64 (+0.52%)
AMC   4.69 (+1.08%)
PFE   38.83 (+1.20%)
PYPL   64.11 (-1.40%)
NFLX   403.04 (+0.94%)
S&P 500   4,269.23 (-0.34%)
DOW   33,663.14 (+0.27%)
QQQ   350.24 (-1.30%)
AAPL   177.97 (-0.69%)
MSFT   324.12 (-2.87%)
META   266.24 (-1.80%)
GOOGL   122.85 (-3.50%)
AMZN   122.36 (-3.36%)
TSLA   226.30 (+2.25%)
NVDA   382.27 (-1.10%)
NIO   7.78 (-1.27%)
BABA   85.40 (-1.50%)
AMD   119.44 (-3.86%)
T   15.91 (+1.53%)
F   13.49 (+4.33%)
MU   67.33 (-0.31%)
CGC   0.73 (-1.69%)
GE   106.53 (+1.01%)
DIS   92.64 (+0.52%)
AMC   4.69 (+1.08%)
PFE   38.83 (+1.20%)
PYPL   64.11 (-1.40%)
NFLX   403.04 (+0.94%)
S&P 500   4,269.23 (-0.34%)
DOW   33,663.14 (+0.27%)
QQQ   350.24 (-1.30%)
AAPL   177.97 (-0.69%)
MSFT   324.12 (-2.87%)
META   266.24 (-1.80%)
GOOGL   122.85 (-3.50%)
AMZN   122.36 (-3.36%)
TSLA   226.30 (+2.25%)
NVDA   382.27 (-1.10%)
NIO   7.78 (-1.27%)
BABA   85.40 (-1.50%)
AMD   119.44 (-3.86%)
T   15.91 (+1.53%)
F   13.49 (+4.33%)
MU   67.33 (-0.31%)
CGC   0.73 (-1.69%)
GE   106.53 (+1.01%)
DIS   92.64 (+0.52%)
AMC   4.69 (+1.08%)
PFE   38.83 (+1.20%)
PYPL   64.11 (-1.40%)
NFLX   403.04 (+0.94%)
S&P 500   4,269.23 (-0.34%)
DOW   33,663.14 (+0.27%)
QQQ   350.24 (-1.30%)
AAPL   177.97 (-0.69%)
MSFT   324.12 (-2.87%)
META   266.24 (-1.80%)
GOOGL   122.85 (-3.50%)
AMZN   122.36 (-3.36%)
TSLA   226.30 (+2.25%)
NVDA   382.27 (-1.10%)
NIO   7.78 (-1.27%)
BABA   85.40 (-1.50%)
AMD   119.44 (-3.86%)
T   15.91 (+1.53%)
F   13.49 (+4.33%)
MU   67.33 (-0.31%)
CGC   0.73 (-1.69%)
GE   106.53 (+1.01%)
DIS   92.64 (+0.52%)
AMC   4.69 (+1.08%)
PFE   38.83 (+1.20%)
PYPL   64.11 (-1.40%)
NFLX   403.04 (+0.94%)
NASDAQ:FDMT

4D Molecular Therapeutics (FDMT) News Today

$18.55
-0.67 (-3.49%)
(As of 02:28 PM ET)
Compare
Today's Range
$18.38
$19.95
50-Day Range
$15.16
$21.81
52-Week Range
$5.32
$26.49
Volume
222,280 shs
Average Volume
464,720 shs
Market Capitalization
$616.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.13
Get 4D Molecular Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.



FDMT Media Mentions By Week

FDMT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

FDMT
News Sentiment

0.95

0.51

Average
Medical
News Sentiment

FDMT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

FDMT Articles
This Week

6

2

FDMT Articles
Average Week

SourceHeadline
finance.yahoo.com logoAndreas Halvorsen's Firm Storms Deeper Into 4D Molecular Therapeutics
finance.yahoo.com - June 7 at 1:13 PM
MarketBeat logo4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Scott Bizily Sells 2,247 Shares
americanbankingnews.com - June 7 at 7:28 AM
marketbeat.com logo4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Rating of "Moderate Buy" from Analysts
marketbeat.com - June 6 at 5:50 AM
marketbeat.com logoCitigroup Inc. Grows Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)
marketbeat.com - June 5 at 4:52 AM
morningstar.com logo4D Molecular Therapeutics Inc Ordinary Shares
morningstar.com - June 3 at 10:02 AM
marketbeat.com logoPeloton Wealth Strategists Has $822,000 Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)
marketbeat.com - June 2 at 2:39 PM
marketbeat.com logoOpaleye Management Inc. Has $7.33 Million Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)
marketbeat.com - May 26 at 2:50 PM
finance.yahoo.com logo4DMT to Present Interim Data from 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis Lung Disease at the European Cystic Fibrosis Society (ECFS) 46th Annual Meeting
finance.yahoo.com - May 24 at 12:23 PM
markets.businessinsider.com logo4D Molecular Therapeutics (FDMT) Gets a Buy from BMO Capital
markets.businessinsider.com - May 24 at 7:23 AM
MarketBeat logo4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Down to $17.82
americanbankingnews.com - May 18 at 6:34 AM
MarketBeat logoQ2 2023 Earnings Estimate for 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Issued By HC Wainwright
americanbankingnews.com - May 16 at 2:30 AM
marketbeat.com logo4D Molecular Therapeutics, Inc. Expected to Post Q2 2023 Earnings of ($0.89) Per Share (NASDAQ:FDMT)
marketbeat.com - May 15 at 2:22 AM
MarketBeat logoAnalysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) PT at $34.13
americanbankingnews.com - May 15 at 1:50 AM
MarketBeat logoInsider Buying: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Major Shareholder Buys 850,000 Shares of Stock
americanbankingnews.com - May 14 at 4:14 AM
MarketBeat logoBrokers Issue Forecasts for 4D Molecular Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:FDMT)
americanbankingnews.com - May 14 at 2:54 AM
finance.yahoo.com logoAndreas Halvorsen's Firm Packs Further Into 4D Molecular Therapeutics
finance.yahoo.com - May 12 at 6:48 PM
marketbeat.com logo4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Up on Insider Buying Activity
marketbeat.com - May 12 at 10:34 AM
marketbeat.com logo4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Forecasted to Earn Q2 2023 Earnings of ($0.61) Per Share
marketbeat.com - May 12 at 8:36 AM
marketbeat.com logo4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
marketbeat.com - May 12 at 5:12 AM
marketbeat.com logo4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Holdings Decreased by SG Americas Securities LLC
marketbeat.com - May 12 at 4:33 AM
finance.yahoo.com logo4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
finance.yahoo.com - May 11 at 12:45 PM
finance.yahoo.com logo4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights
finance.yahoo.com - May 10 at 4:15 PM
marketbeat.com logo12,036 Shares in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Bought by Mitsubishi UFJ Kokusai Asset Management Co. Ltd.
marketbeat.com - May 10 at 4:43 AM
finance.yahoo.com logo4D Molecular Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - May 9 at 7:53 PM
MarketBeat logo4D Molecular Therapeutics (FDMT) to Release Quarterly Earnings on Wednesday
americanbankingnews.com - May 9 at 9:08 AM
MarketBeat logo4D Molecular Therapeutics (FDMT) Set to Announce Quarterly Earnings on Wednesday
americanbankingnews.com - May 9 at 8:16 AM
finance.yahoo.com logo4D Molecular Therapeutics, Inc. (FDMT) Surges 5.4%: Is This an Indication of Further Gains?
finance.yahoo.com - May 8 at 8:35 AM
seekingalpha.com logo4D Molecular Therapeutics prices $120M share offering
seekingalpha.com - May 5 at 7:52 AM
finance.yahoo.com logo4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
finance.yahoo.com - May 4 at 9:50 PM
msn.com logoHC Wainwright & Co. Reiterates 4D Molecular Therapeutics (FDMT) Buy Recommendation
msn.com - April 28 at 5:48 PM
markets.businessinsider.com logoH.C. Wainwright Sticks to Their Buy Rating for 4D Molecular Therapeutics (FDMT)
markets.businessinsider.com - April 28 at 7:45 AM
MarketBeat logo4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Sells $75,000.00 in Stock
americanbankingnews.com - April 28 at 5:50 AM
MarketBeat logoInsider Selling: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Director Sells $100,250.00 in Stock
americanbankingnews.com - April 28 at 5:50 AM
msn.com logo4D Molecular Therapeutics Sinks on Latest Drug Trial
msn.com - April 27 at 4:44 PM
finance.yahoo.com logo4DMT Presents Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ARVO 2023
finance.yahoo.com - April 27 at 9:51 AM
finance.yahoo.com logo4DMT Acquires Complement Pathway Inhibitor Payload for 4D-175 Product Candidate for Geographic Atrophy
finance.yahoo.com - April 24 at 8:30 AM
finance.yahoo.com logoAevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor H
finance.yahoo.com - April 24 at 8:30 AM
MarketBeat logo4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $34.13 Average PT from Analysts
americanbankingnews.com - April 24 at 5:28 AM
marketbeat.com logoAllspring Global Investments Holdings LLC Sells 8,190 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)
marketbeat.com - April 20 at 4:19 AM
MarketBeat logo4D Molecular Therapeutics (NASDAQ:FDMT) Trading 6.4% Higher
americanbankingnews.com - April 19 at 6:54 AM
MarketBeat logoFY2024 EPS Estimates for 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Boosted by SVB Leerink
americanbankingnews.com - April 18 at 2:42 AM
marketbeat.com logoFY2024 Earnings Forecast for 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Issued By SVB Leerink
marketbeat.com - April 17 at 2:36 AM
MarketBeat logoSVB Securities Lowers 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $13.00
americanbankingnews.com - April 16 at 3:30 AM
MarketBeat logo4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Down on Analyst Downgrade
americanbankingnews.com - April 15 at 1:20 AM
finance.yahoo.com logo4D Molecular Therapeutics, Inc. (FDMT) Soars 11.2%: Is Further Upside Left in the Stock?
finance.yahoo.com - April 14 at 7:46 AM
msn.com logoSVB Securities Maintains 4D Molecular Therapeutics (FDMT) Market Perform Recommendation
msn.com - April 13 at 9:25 PM
markets.businessinsider.com logoSVB Securities Maintains Market Perform Rating for 4D Molecular Therapeutics: Here's What You Need To Know
markets.businessinsider.com - April 13 at 4:24 PM
markets.businessinsider.com logoThe Latest Analyst Ratings for 4D Molecular Therapeutics
markets.businessinsider.com - April 13 at 4:24 PM
finance.yahoo.com logo4DMT to Present Interim Data from 4D-150 Phase 1/2 PRISM Clinical Trial for Wet AMD at ARVO 2023, and Promotes Robert Kim, M.D. to Chief Medical Officer
finance.yahoo.com - April 13 at 10:13 AM
finance.yahoo.com logoIs 4D Molecular Therapeutics (NASDAQ:FDMT) In A Good Position To Invest In Growth?
finance.yahoo.com - April 12 at 9:33 AM
Get 4D Molecular Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:FDMT) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -